Problem

Kerna Laboratories addresses the central bottleneck in mRNA medicines: designing RNA payloads that translate efficiently, remain stable long enough to work, and express in the intended cell types. Although mRNA has proven transformative for infectious disease, payload-design and delivery limitations have restricted its use across broader therapeutic areas, increasing biological and development risk while narrowing the set of conditions that can realistically be treated.

The main use case is creating better mRNA payloads for genetic medicine, particularly protein-replacement therapies and treatments for previously untreatable conditions. By improving translatability, durability, tissue specificity, and manufacturability, Kerna aims to make mRNA a more practical platform for a wider range of diseases rather than a technology primarily associated with vaccines.

Product / Service

Kerna is building an AI foundation-model platform for mRNA therapeutics. It combines large-scale machine learning with high-throughput biology to decode RNA behavior and design optimized sequences. The platform is intended to tune expression curves, produce cell-type-specific expression, increase protein output, and extend the effective half-life of mRNA through greater stability.

The company appears to be pursuing a partner-enabled platform model rather than selling a conventional standalone software product: its public materials invite collaborations with organizations developing mRNA pipelines. The benefit for those partners is faster and more systematic payload design, with sequences engineered for greater potency, targeting precision, and duration of effect.

Market

Kerna competes at the intersection of AI-native drug discovery, computational RNA design, mRNA therapeutics, and genetic medicine. Its closest publicly identifiable adjacent competitor is Deep Genomics, which uses its BigRNA AI platform to develop RNA-based therapeutics. The broader competitive set also includes internal pharmaceutical mRNA-design teams, academic AI models, and other computational RNA and delivery platforms, although Kerna's specific foundation-model positioning is differentiated around therapeutically optimized mRNA sequences.

Kerna is an early-stage, pre-commercial biotech rather than a company with publicly demonstrated revenue or clinical products. It was founded in 2024, emerged from stealth in January 2025 with its AI platform, and closed an oversubscribed seed round backed by Gradient, Humba Ventures, Tau Ventures, Pioneer Fund, Focalpoint Partners, and prominent angels. The public record shows meaningful investor validation and an operating platform, but does not disclose named customers, revenue, clinical candidates, or regulatory milestones.